Perfil antiinflamatorio del paricalcitol en el receptor de trasplante renal

Donate-Correa, Javier; Henríquez-Palop, Fernando; Martín‐Núñez, Ernesto; Hernández-Carballo, Carolina; Ferri, Carla; Pérez‐Delgado, Nayra; Muros‐de‐Fuentes, Mercedes; Mora‐Fernández, Carmen; Navarro‐González, Juan F.

doi:10.1016/j.nefro.2017.03.028

Cited by 5 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An observational study in RTRs with secondary hyperparathyroidism found that 3 months of treatment with paricalcitol reduced serum IL-6 and TNF levels, with corresponding lowered mRNA expression in peripheral blood mononuclear cells [29]. In a clinical trial of 168 RTRs with proteinuria, paricalcitol treatment on top of RAAS-blockade caused significant reductions in circulating IL-6 and the pro-fibrotic mediator transforming growth factor beta (TGFβ) [30].…”

Section: Introductionmentioning

confidence: 99%

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients

et al. 2020

View full text Add to dashboard Cite

Following a successful renal transplantation circulating markers of inflammation may remain elevated, and systemic inflammation is associated with worse clinical outcome in renal transplant recipients (RTRs). Vitamin D-receptor (VDR) activation is postulated to modulate inflammation and endothelial function. We aimed to explore if a synthetic vitamin D, paricalcitol, could influence systemic inflammation and immune activation in RTRs. Newly transplanted RTRs were included in an open-label randomized controlled trial on the effect of paricalcitol on top of standard care over the first post-transplant year. Fourteen pre-defined circulating biomarkers reflecting leukocyte activation, endothelial activation, fibrosis and general inflammatory burden were analyzed in 74 RTRs at 8 weeks (baseline) and 1 year post-engraftment. Mean changes in plasma biomarker concentrations were compared by t-test. The expression of genes coding for the same biomarkers were investigated in 1-year surveillance graft biopsies (n = 60). In patients treated with paricalcitol circulating osteoprotegerin levels increased by 0.19 ng/ml, compared with a 0.05 ng/ml increase in controls (p = 0.030). In graft tissue, a 21% higher median gene expression level of TNFRSF11B coding for osteoprotegerin was found in paricalcitol-treated patients compared with controls (p = 0.026). Paricalcitol treatment did not significantly affect the blood- or tissue levels of any other investigated inflammatory marker. In RTRs, paricalcitol treatment might increase both circulating and tissue levels of osteoprotegerin, a modulator of calcification, but potential anti-inflammatory treatment effects in RTRs are likely very modest. [NCT01694160 (2012/107D)]; [www.clinicaltrials.gov].

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Untitled

View full text Add to dashboard Cite

Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients

et al. 2018

View full text Add to dashboard Cite

IntroductionLow serum vitamin D levels are associated with the development of poststroke depression (PSD). Inflammatory markers play an important role in pathophysiology of PSD. The relationship between vitamin D levels and inflammatory markers has been discussed in nonstroke individuals. The purposes of this study were to explore the relationship between vitamin D levels and inflammatory markers in acute stroke patients and examine the effect of vitamin D and inflammatory markers on PSD.MethodsA total of 152 acute stroke patients were recruited. Serum levels of 25‐hydroxyvitamin D and inflammatory markers were measured by standardized laboratory methods. Depression symptoms were assessed with the 17‐item Hamilton Depression Scale (HAMD‐17). Patients with the HAMD‐17 scores ≥7 were identified to have depression symptoms.ResultsSerum vitamin D levels were negatively correlated with serum levels of interleukin‐6 and high‐sensitivity C‐reactive protein (hsCRP) (r = −.244, p = .002; r = −.231, p = .004). Multiple regression analysis showed that interleukin‐6 and hsCRP levels were associated with vitamin D levels (B = −0.355, p = .003; B = −2.085, p = .006), whereas age, height, weight, leukocyte count, neutrophil ratio, and lymphocyte rate could be omitted without changing the results. In multivariate analyses, the serum levels of vitamin D and interleukin‐6 were associated with the development of PSD after adjusted possible variables (OR = 0.976, 95% CI: 0.958–0.994, p = .009; OR = 1.029, 95% CI: 1.003–1.055, p = .027).ConclusionsSerum vitamin D levels are inversely associated with the levels of interleukin‐6 and hsCRP, suggesting a potential anti‐inflammatory role for vitamin D in stroke individuals.

show abstract

Perfil antiinflamatorio del paricalcitol en el receptor de trasplante renal

Abstract: Paricalcitol administration to kidney transplant recipients has been found to have beneficial effects on inflammation, which may be associated with potential clinical benefits.

Cited by 5 publications

References 39 publications

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients

Untitled

Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients

Contact Info

Product

Resources

About